Table 2.
Studies Evaluating the Association Between DAA Therapy and Recurrent HCC
| First Author | Year | Data Source | HCC Treatments | Median Time From HCC Treatment to DAA Initiation (Months) | Start of Follow‐up | Median Duration of Follow‐up in Patients Treated with DAA (Months) | Number of Patients Treated With DAA | Number of Controls | HCC Recurrence (Proportion) | Comparison of HCC Recurrence in Patients Treated With DAA Versus Controls |
|---|---|---|---|---|---|---|---|---|---|---|
| Reig16 | 2016 | Spanish multicenter cohort | Resection | 11.2 | Antiviral initiation | 5.7 | 58 | — | 27.6% | — |
| Radiofrequency ablation | ||||||||||
| Chemoembolization | ||||||||||
| Conti6 | 2016 | Italian regional database | Resection | 12.4 | Antiviral completion | 6 | 59 | — | 28.8% | — |
| Radiofrequency ablation | ||||||||||
| Chemoembolization | ||||||||||
| Percutaneous ethanol | ||||||||||
| Bielen23 | 2017 | Belgian multicenter cohort | Liver transplant | 12 | Antiviral completion | — | 41 | — | 15% | — |
| Resection | ||||||||||
| Radiofrequency ablation | ||||||||||
| Chemoembolization | ||||||||||
| Cabibbo24 | 2017 | Italian regional database | Resection | 11 | Antiviral initiation | 8.7 | 143 | — | 20.3% | — |
| Radiofrequency ablation | ||||||||||
| Chemoembolization | ||||||||||
| Ogawa25 | 2018 | Japanese multicenter cohort | Resection | 14.4 | Antiviral initiation | 17 | 152 | — | 17.1% | — |
| Radiofrequency ablation | ||||||||||
| Chemoembolization | ||||||||||
| Radioembolization | ||||||||||
| ANRS17 | 2016 | French multicenter cohort | — | 21.6* | Antiviral initiation | 20.2 | 189 | 78 (untreated) | 12.7% | aHR, 1.09 (95% CI, 0.55‐2.16) |
| ANRS17 | 2016 | French multicenter cohort | Resection | __ | Antiviral initiation | 21.3 | 13 | 66 (untreated) | 7.7% | HR, 0.40 (95% CI, 0.05‐3.03) |
| Radiofrequency ablation | ||||||||||
| Ikeda26 | 2017 | Japanese single center | Resection | 10.7 | Antiviral initiation | 21.5 | 89 | 89 (untreated) | 19.3% | aHR, 0.35 (95% CI, 0.19‐0.65) |
| Radiofrequency ablation | ||||||||||
| Chemoembolization | ||||||||||
| Particle radiation therapy | ||||||||||
| Nagata19 | 2017 | Japanese multicenter cohort | Resection | — | HCC curative treatment | 27.6 | 83 | 60 (IFN treated) | 22.9% DAA + SVR | P = 0.022 |
| Radiofrequency ablation | ||||||||||
| 40.0% DAA − SVR | ||||||||||
| (3‐year incidence) | ||||||||||
| 45.1% DAA | P = 0.54 | |||||||||
| 54.2% IFN | ||||||||||
| (5‐year incidence) | ||||||||||
| Virlogeux21 | 2017 | French single center | Resection | 7.2 | Antiviral initiation | — | 23 | 45 (untreated) | 47.8% | HR, 0.24 (95% CI, 0.10‐0.55) |
| Radiofrequency ablation | ||||||||||
| Chemoembolization | ||||||||||
| Huang18 | 2018 | US single center | Resection | 11.9† | Complete response | — | 61 | 51 (untreated) | 47% DAA | aHR, 0.91 (95% CI, 0.58‐1.42) |
| Radiofrequency ablation | 49.8% no DAA | |||||||||
| (1‐year incidence) | ||||||||||
| Cryotherapy | ||||||||||
| Percutaneous ethanol | ||||||||||
| Mashiba20 | 2018 | Japanese multicenter cohort | — | 10.9 | Antiviral completion | 7.7 | 368 | 148 (IFN treated) | — | HR, 0.95 (95% CI, 0.61‐1.45)‡ |
*
From HCC diagnosis to inclusion in cohort.
†
From HCC diagnosis to DAA initiation.
‡
IFN versus DAA therapy, restricted to SVR patients.